WuXi XDC Cayman Inc. (FRA:L74)

Market Cap	7.75B +41.3%
Revenue (ttm)	723.82M +46.7%
Net Income	180.28M +38.4%
EPS	0.14 +34.9%
Shares Out	n/a
PE Ratio	43.00
Forward PE	28.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18
Open	6.10
Previous Close	6.30
Day's Range	6.05 - 6.30
52-Week Range	4.22 - 9.55
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m...

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 2,662
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: L74

Financial Performance

In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error